cabazitaxel injection (BH002) / Zhuhai Beihai Biotech - LARVOL DELTA

BH002-Ⅰ-101: Phase I Clinical Trial of BH002 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: Zhuhai Beihai Biotech Co., Ltd

New P1 trial • Oncology • Solid Tumor

Biweekly Cabazitaxel for mCRPC Safe for Men Aged 65+ (Renal and Urology News) - "Cabazitaxel is an important option for men with advanced treatment-resistant prostate cancer, and biweekly dosing appears to be well suited in those who are older and have received prior pelvic radiation, noted Tomasz Beer, MD...Dr Beer pointed out that the trial was not powered as a non-inferiority study for cancer outcomes. Rather, it was designed and powered to show superiority with regard to neutropenic complications."

Media quote

The ACDC-RP Phase II Trial: Understanding the Impact on High-Risk Prostate Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen (Urotoday) - "Zach Klaassen is joined by...to analyze the ACDC-RP Phase II Trial concerning neoadjuvant therapy in high-risk prostate cancer patients. The trial focuses on the combination of cabazitaxel, abiraterone, and leuprolide, examining the high treatment failure rates and mortality in this patient group. The discussion details the trial's design, methodology, endpoints, and safety assessments while emphasizing early treatment intensification."

Video

Podcast: ASCO23: Novel Approaches in RCC, mUC, and Prostate Cancer (ASCO Daily News) - "Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss the CLEAR study in renal cell carcinoma, a new exploratory analysis combining the TheraP and VISION trials in metastatic urothelial cancer, and compelling advances in prostate cancer and across GU oncology in advance of the 2023 ASCO Annual Meeting."

Audio • Renal Cell Carcinoma